ANI Pharmaceuticals Inc
ANIP
Market Cap$1.27B
Close$
$-54.62
191.2% downside
Current Fair Value
191.2% downsideOvervalued by 191.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.27 Billion |
|---|---|
| Enterprise Value | $1.52 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.87 |
| Beta | 0.56 |
| Outstanding Shares | 19,607,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -54.7 |
|---|---|
| PEG | 394.27 |
| Price to Sales | 1.76 |
| Price to Book Ratio | 2.72 |
| Enterprise Value to Revenue | 2.26 |
| Enterprise Value to EBIT | -191.16 |
| Enterprise Value to Net Income | -73 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.95 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...